Sitagliptin / Metformin hydrochloride Sun 欧盟 - 法文 - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride sun

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

FONZYLANE 50 mg/5 ml, solution injectable 法国 - 法文 - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

fonzylane 50 mg/5 ml, solution injectable

cephalon france - buflomédil (chlorhydrate de) - solution - 50 mg - composition pour une ampoule > buflomédil (chlorhydrate de) : 50 mg - autres vasodilatateurs peripheriques

FONZYLANE 150 mg, comprimé pelliculé 法国 - 法文 - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

fonzylane 150 mg, comprimé pelliculé

cephalon france - buflomédil (chlorhydrate de) - comprimé - 150 mg - composition pour un comprimé > buflomédil (chlorhydrate de) : 150 mg - autres vasodilatateurs peripheriques

FONZYLANE 400 mg/120 ml, solution injectable pour perfusion en poche 法国 - 法文 - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

fonzylane 400 mg/120 ml, solution injectable pour perfusion en poche

cephalon france - chlorhydrate de buflomédil - solution - 0,400 g - composition pour une poche de 120 ml > chlorhydrate de buflomédil : 0,400 g - autres vasodilatateurs peripheriques

Sitagliptin / Metformin hydrochloride Mylan 欧盟 - 法文 - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Vildagliptin / Metformin hydrochloride Accord 欧盟 - 法文 - EMA (European Medicines Agency)

vildagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabète sucré, type 2 - les médicaments utilisés dans le diabète - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 et 5. 1 pour les données disponibles sur différentes combinaisons).

Sitagliptin / Metformin hydrochloride Accord 欧盟 - 法文 - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triple thérapie de combinaison) en complément d'un régime alimentaire et l'exercice chez les patients insuffisamment contrôlés sur leur dose maximale tolérée de metformine et une sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

FONZYLANE 300 mg, comprimé pelliculé 法国 - 法文 - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

fonzylane 300 mg, comprimé pelliculé

cephalon france - buflomédil (chlorhydrate de) - comprimé - 300 mg - composition pour un comprimé > buflomédil (chlorhydrate de) : 300 mg

LOFTYL 150 mg, comprimé pelliculé 法国 - 法文 - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

loftyl 150 mg, comprimé pelliculé

amdipharm ltd - buflomédil (chlorhydrate de) - comprimé - 150 mg - composition pour un comprimé > buflomédil (chlorhydrate de) : 150 mg

LOFTYL 50 mg/5 ml, solution injectable 法国 - 法文 - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

loftyl 50 mg/5 ml, solution injectable

amdipharm ltd - buflomédil (chlorhydrate de) - solution - 50 mg - composition pour 5 ml > buflomédil (chlorhydrate de) : 50 mg